Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Migraine therapy].

H-C Diener1, V Limmroth

  • 1Universitätsklinik für Neurologie, Essen. h.diener@uni-essen.de

Der Internist
|July 5, 2005
PubMed
Summary
This summary is machine-generated.

Migraine affects millions, but new treatments offer hope. Advances in understanding headache pathophysiology and pharmacology now enable personalized acute and preventative care for migraine sufferers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MMW Fortschritte der Medizin·2020
Same author

MMW Fortschritte der Medizin·2020
Same author

MMW Fortschritte der Medizin·2020
Same author

MMW Fortschritte der Medizin·2020
Same author

MMW Fortschritte der Medizin·2019
Same author

MMW Fortschritte der Medizin·2019

Area of Science:

  • Neurology
  • Pharmacology
  • Genetics

Background:

  • Migraine is a prevalent neurological disorder affecting over 8 million people in Germany.
  • Recent advancements in understanding migraine pathophysiology and genetics have significantly improved treatment options.
  • Developments in pharmacology have led to better acute and preventative care strategies.

Purpose of the Study:

  • To review current advancements in migraine treatment and prevention.
  • To highlight the availability of customized treatment options for migraine attacks.
  • To discuss new and established drugs for migraine prevention tailored to individual patient needs.

Main Methods:

  • Review of approved 5-HT(1B/D)-agonists (triptans) for acute migraine treatment.
  • Analysis of newly available and established drugs for migraine prevention.

Related Experiment Videos

  • Discussion of personalized treatment approaches based on individual patient needs.

    • Main Results:

    • Seven triptan substances with 23 dosages/formulations are approved for customized acute migraine treatment.
    • Valproic acid and topiramate are now first-choice drugs for migraine prevention.
    • Established beta blockers remain crucial for preventative migraine therapy.

    Conclusions:

    • Personalized treatment strategies for both acute and preventative migraine care are now more effective.
    • Physicians can tailor migraine management to individual patient requirements using available pharmacological options.
    • Ongoing research in pathophysiology and genetics continues to drive therapeutic innovation for migraine.